A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

• Status: WITHDRAWN
• Trial end date: 2026-02-01

Summary

The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age 12 to \<18 years old abruptly discontinuing opioid use.

• Phase: PHASE1

Details

• Lead Sponsor: USWM, LLC (dba US WorldMeds)
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: lofexidine; Tablets